Seminars in Arthritis and Rheumatism

Journal

Publication Venue For

  • Denosumab did not improve computerized tomography erosion scores when added to intensive urate-lowering therapy in gout: Results from a pilot randomized controlled trial.  51:1218-1223. 2021
  • Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group.  51:1378-1385. 2021
  • Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report.  51:1108-1112. 2021
  • Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group.  51:946-950. 2021
  • Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach.  51:593-600. 2021
  • Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: A qualitative exploration from the OMERACT CPPD working group.  51:655-660. 2021
  • OMERACT 2020: A virtual (R)evolution.  51:588-592. 2021
  • OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study.  51:601-606. 2021
  • Outcome domains reported by patients, caregivers, healthcare professionals and stakeholders for calcium pyrophosphate deposition (CPPD): A content analysis based on semi-structured qualitative interviews from the OMERACT CPPD working group.  51:650-654. 2021
  • Association of cardiovascular disease and traditional cardiovascular risk factors with the incidence of dementia among patients with rheumatoid arthritis.  51:292-298. 2021
  • Advances in our understanding of gout as an auto-inflammatory disease.  50:1089-1100. 2020
  • Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis.  50:988-995. 2020
  • Outcome domains reported in calcium pyrophosphate deposition studies: A scoping review by the OMERACT CPPD working group.  50:719-727. 2020
  • The experience of a gout flare: a meta-synthesis of qualitative studies.  50:805-811. 2020
  • Gout epidemiology and comorbidities.  50:S11-S16. 2020
  • How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials.  50:303-313. 2020
  • Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study.  50:228-236. 2020
  • Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis.  48:293-301. 2018
  • An association of smoking with serum urate and gout: A health paradox.  47:825-842. 2018
  • Medication adherence among patients with gout: A systematic review and meta-analysis.  47:689-702. 2018
  • Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis.  47:472-477. 2018
  • Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort.  47:199-203. 2017
  • Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials.  46:699-708. 2017
  • Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort.  45:675-683. 2016
  • Rituximab-induced serum sickness: A systematic review.  45:334-340. 2015
  • Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources.  44:381-388. 2015
  • Impaired response or insufficient dosage?-Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.  44:170-174. 2014
  • Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.  43:489-497. 2014
  • Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients.  43:137-143. 2013
  • The association between meniscal damage of the posterior horns and localized posterior synovitis detected on T1-weighted contrast-enhanced MRI-The MOST study.  42:573-581. 2013
  • Cardiopulmonary Complications After Primary Shoulder Arthroplasty: A Cohort Study.  41:689-697. 2012
  • Health Care Utilization in Patients with Gout.  40:501-511. 2011
  • Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus.  39:257-268. 2010
  • A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries1.  40:2-14.e1. 2010
  • Systemic Nonarticular Manifestations of Rheumatoid Arthritis: Focus on Inflammatory Mechanisms.  39:132-143. 2009
  • Health-related quality of life predicts future health care utilization and mortality in veterans with self-reported physician-diagnosed arthritis: The veterans arthritis quality of life study.  34:755-765. 2005
  • Estrogen and Other Female Reproductive Risk Factors Are Not Strongly Associated With the Development of Rheumatoid Arthritis in Elderly Women.  33:72-82. 2003
  • Cartilage imaging in osteoarthritis.  25:273-281. 1996
  • Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): A decision analysis model.  25:297-307. 1996
  • HLA in ankylosing spondylitis: Is HLA-B27 the only MHC gene involved in disease pathogenesis?.  23:295-309. 1994
  • The future of biologies in the treatment of rheumatoid arthritis.  23:50-58. 1994
  • Spinal stenosis: A comprehensive review of the literature.  19:127-149. 1989
  • The infectious etiology of chronic rheumatic diseases.  17:1-23. 1987
  • CREG antigens differentially influence expression of extraarticular manifestations in whites and blacks with rheumatoid arthritis.  13:169-173. 1983
  • Articular involvement in human Brucellosis: A retrospective analysis of 304 cases.  12:245-255. 1982
  • Saturnine gout: A review of 42 patients.  11:307-314. 1982
  • International Standard Serial Number (issn)

  • 0049-0172
  • Electronic International Standard Serial Number (eissn)

  • 1532-866X